Author Archive

BCI 2017 Report and Results Released

Posted by:

Pugatch Consilium has released the 2017 Biopharmaceutical Competitiveness & Investment (BCI) Survey. An executive opinion survey, in 2017 the BCI polled business leaders and local general managers from the biopharmaceutical industry about the investment environment in 31 markets. The results are available in the linked report below.

 

The headline results of the 2017 BCI Survey include:

 

  • The policy environment matters a great deal for biopharmaceutical investment decisions. Economies with policies supporting biopharmaceutical innovation and investment are much more likely to actually secure ...
Continue Reading →
0

Preliminary BCI 2017 Results and New Impact Analysis Published

Posted by:

In a world of global investment flows, securing a larger portion of the $150 billion invested per year by the research-based biopharmaceutical industry is anyone’s game. The 2017 results of the annual Biopharmaceutical Competitiveness & Investment (BCI) Survey, previewed at the International BIO Convention in San Diego in June, reveal that biopharmaceutical competitiveness turns on the policy conditions that countries decide to put in place.

 

A new blog post by Prof Meir Pugatch on PhRMA’s The Catalyst discusses these results and ...

Continue Reading →
0

Pugatch Consilium launches 2016 BCI Survey

Posted by:

Pugatch Consilium has launched the third edition of the Biopharmaceutical Competitiveness & Investment (BCI) Survey: The Race for Biopharmaceutical Innovation.

A global executive opinion survey and index of economies’ attractiveness for biomedical investment, in 2016 the BCI covers 28 strategic markets and gauges individual markets in relation to others with similar levels of development. The study was released in Washington DC and Ottawa, Canada, with other local and regional launches to take place throughout the remainder of the year.

Key findings of the ...

Continue Reading →
0

Pugatch Consilium at the International BIO Convention

Posted by:

Yesterday, June 16th 2015, Prof Meir Pugatch presented the findings of two of Pugatch Consilium’s latest studies at an opening plenary session of the International BIO Convention in Philadelphia, Pennsylvania. During the session, Prof Pugatch discussed empirical measures of national biopharmaceutical environments, including the Biopharmaceutical Competitiveness & Investment (BCI) Survey and Building the Bioeconomy 2015, and how these tools can be used to shed light on emerging opportunities and challenges in global biotech markets.

 

The results of the two studies are also being presented in additional panels ...

Continue Reading →
0

New Study: Policy Environment Has a Significant Impact on Biopharmaceutical Investment

Posted by:

Economies’ policy trajectories have a significant impact on biopharmaceutical investment decisions, perhaps more than costs and market size, according to local executives. Our new study, Measuring the Global Biomedical Pulse: The Biopharmaceutical Investment & Competitiveness (BCI) Survey, finds that economies with policy environments that support investment and innovation rank as the most attractive for biopharmaceutical investment in the eyes of top level executives operating on the ground. The study, commissioned by PhRMA, also finds that notwithstanding low costs and considerable ...

Continue Reading →
0

How to Stay One Step Ahead of an Outbreak

Posted by:

Pugatch Consilium’s Prof. Meir Pugatch and Rachel Chu publish an article in fDi Magazine (http://www.fdiintelligence.com/) on how building an innovation culture can help countries prepare for the outbreak of diseases such as Ebola. The article is part of Pugatch Consilium’s ongoing analysis and intelligence database on biopharmaceutical investment and innovation policy.

How to stay one step ahead of an outbreak  – Read more on our Research & Analysis Reports Page

Continue Reading →
0

The US Chamber and Pugatch Consilium launch the third edition of the GIPC IP Index

Posted by:

This week Pugatch Consilium, in partnership with the US Chamber’s Global Intellectual Property Center, released the third edition of the annual GIPC International IP Index. The 2015 edition of the Index, entitled UP: Unlimited Potential, maps the intellectual property environment in 30 economies. Overall, although challenges remain across the board, positive steps are being taken in many of the economies included in the Index. In fact, 20 of the economies mapped in 2014 improved their scores in the 2015 edition. The ...

Continue Reading →
0

New article in IP Today – Staying Ahead: How Can Robust IP Protection Help Countries Prepare for the Next Ebola?

Posted by:

This week IP Today published an article by Pugatch Consilium Partner, Rachel Chu.

Looking at the race to develop the Ebola vaccine as well as other new medicines, the article draws a connection between investment in R&D, clinical trials and the protection of IPRs – all aimed at developing next generation healthcare technologies and medicines.

“Although increasing resources directed towards the health system is among the most obvious steps policymakers can take, one element often overlooked is the level of support toward ...

Continue Reading →
0

Understanding the drivers of biopharmaceutical clinical research: Why do some countries get all the investment?

Posted by:

Today Pugatch Consilium releases Scaling Up Global Clinical Trial Activity: Key Trends and Policy Lessons. This study uses regression analysis of data on 50 countries to provide a roadmap for creating a policy environment that is conducive to clinical trials. The study also benchmarks performance in the level of scope of clinical trial activity.
The main messages of the report are:

  • The creation of a pro-innovation culture is just as, if not more, important as improvements to health system capacity for ...
Continue Reading →
0
Page 1 of 4 1234